EP3355880A1 — New use
Assigned to Novartis AG · Expires 2018-08-08 · 8y expired
What this patent protects
The present invention relates to methods and pharmaceutical compositions for reducing arterial stiffness in a human patient showing at least one symptom selected from increased pulse wave velocity (PWV) and increased pulse pressure (PP) comprising administration to said patient o…
USPTO Abstract
The present invention relates to methods and pharmaceutical compositions for reducing arterial stiffness in a human patient showing at least one symptom selected from increased pulse wave velocity (PWV) and increased pulse pressure (PP) comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof in a 1:1 molar ratio.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.